Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control

BackgroundGLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with o...

Full description

Bibliographic Details
Main Authors: Rasmus Stenlid, Sara Y. Cerenius, Quan Wen, Banu Küçükemre Aydin, Hannes Manell, Azazul Chowdhury, Hjalti Kristinsson, Iris Ciba, Erik S. Gjessing, Katharina Mörwald, Julian Gomahr, Verena Heu, Daniel Weghuber, Anders Forslund, Peter Bergsten
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Endocrinology
Subjects:
obesity
GLP-1
GLP-1 receptor analog
exenatide
pediatrics
glycemic control
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1293093/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1293093/full

Similar Items